Edition:
United Kingdom

Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

12.32USD
23 Apr 2019
Change (% chg)

$0.01 (+0.08%)
Prev Close
$12.31
Open
$12.32
Day's High
$12.32
Day's Low
$12.32
Volume
207
Avg. Vol
29,497
52-wk High
$14.04
52-wk Low
$4.01

Latest Key Developments (Source: Significant Developments)

Constellation Pharmaceuticals Says Entered Into A Loan And Security Agreement
Thursday, 21 Mar 2019 

March 21 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS INC - ENTERED INTO A LOAN AND SECURITY AGREEMENT.CONSTELLATION PHARMACEUTICALS INC - TERM LOAN OF UP TO AN AGGREGATE PRINCIPAL AMOUNT OF $40.0 MILLION IS AVAILABLE TO COMPANY.CONSTELLATION PHARMACEUTICALS INC - LOAN AGREEMENT PROVIDES FOR AN INITIAL TERM LOAN ADVANCE OF $20.0 MILLION.CONSTELLATION PHARMACEUTICALS INC - TERM LOAN BEARS INTEREST AT AN ANNUAL RATE EQUAL TO GREATER OF 8.55% AND PRIME RATE OF INTEREST PLUS 2.55%..  Full Article

Constellation Pharmaceuticals Announces Fourth-Quarter And Full-Year 2018 Financial Results
Thursday, 14 Mar 2019 

March 14 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.77.Q4 EARNINGS PER SHARE ESTIMATE $-0.74 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2018 DECREASED 10.8% TO $114.6 MILLION COMPARED TO SEPTEMBER 30, 2018.EXPECT THAT CASH AND CASH EQUIVALENTS WILL FUND OPERATING EXPENSES AND CAPEX REQUIREMENTS INTO Q2 OF 2020.  Full Article

Constellation Pharma Inc Says Post-IPO Cash Expected To Fund Operations Into Q2 2020
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS INC - POST-IPO CASH EXPECTED TO FUND OPERATIONS INTO Q2 2020.  Full Article

Constellation Pharma Initiates Phase 2 Portion Of Prostar Clinical Trial In Patients With Type Of Prostate Cancer
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS INITIATES PHASE 2 PORTION OF PROSTAR CLINICAL TRIAL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).CONSTELLATION PHARMACEUTICALS INC - PRELIMINARY PHASE 1B RESULTS SUGGEST CPI-1205 IS WELL-TOLERATED.CONSTELLATION PHARMACEUTICALS INC - CONTINUES TO EXPECT TO DETERMINE PROOF OF CONCEPT FOR CPI-1205 IN MID-2019..  Full Article

Constellation Pharmaceuticals Reports Q3 Loss Per Share Of $0.81
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS ANNOUNCES THIRD-QUARTER AND NINE-MONTH 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.81.Q3 EARNINGS PER SHARE VIEW $-0.67 -- THOMSON REUTERS I/B/E/S.EXPECTS TO EVALUATE PROOF OF CONCEPT FOR CPI-1205 AND CPI-0610 PROGRAMS IN MID-2019.CONSTELLATION PHARMACEUTICALS - EXPECT CASH AS OF SEPT 30, 2018, WILL FUND PLANNED OPERATIONS INTO Q1 2020.  Full Article

Constellation Pharmaceuticals Shares Debut At $11.48, About 23 Pct Below IPO Price
Thursday, 19 Jul 2018 

July 19 (Reuters) - :CONSTELLATION PHARMACEUTICALS SHARES DEBUT AT $11.48 ON NASDAQ VERSUS IPO PRICE OF $15.00/SHARE.  Full Article

Constellation Pharmaceuticals Announces Pricing Of Initial Public Offering
Thursday, 19 Jul 2018 

July 18 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 4.00 MILLION COMMON SHARES PRICED AT $15.00PER SHARE.  Full Article

Constellation Pharma Sees IPO Of 5.3 Mln Shares Priced $14-$16 Per Share
Monday, 9 Jul 2018 

July 9 (Reuters) - Constellation Pharmaceuticals Inc ::CONSTELLATION PHARMACEUTICALS INC - SEES IPO OF 5.3 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $14.00 AND $16.00 PER SHARE.  Full Article